Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
2 results loaded, newest first. End of these results.
Immunic said four abstracts on vidofludimus calcium were accepted for presentation at the MSToronto2026 multiple sclerosis meeting in Toronto later this month. The company also cited new Phase 2 CALLIPER open-label extension data and exploratory biomarker and preclinical findings.
Immunic said four accepted abstracts on vidofludimus calcium will be presented at the October 21-23 MSToronto2026 meeting in Toronto. The company also highlighted new CALLIPER open-label extension data and preclinical and biomarker findings in multiple sclerosis.